Navigation Links
Occlutech Obtains Favourable Ruling in Proceedings Initiated by AGA Medical

JENA, Germany, March 19 /PRNewswire/ -- Occlutech GmbH today announced that it had defeated a request for insolvency, launched at the Amtsgericht Gera in Germany by its US competitor AGA Medical.

The request by AGA was based on wrongful assumptions about Occlutech, and AGA announced that it had started the said request to recover damages. However, the court - Amtsgericht Gera in Germany - stated, that a proceeding regarding any damages has not yet been started.

"Occlutech intends to maintain a healthy business in vascular intervention based on excellent products for cardiac occlusion as well as coronary and peripheral intervention. We have developed a new range of innovative occluders for treating PFO and ASD in order not to violate the recent German patent ruling," said Tor Peters who was appointed CEO in late January and continued: "We expect to be on the market shortly with the new version."

Occlutech won against AGA Medical in the Patent Court in The Hague in October last year. AGA Medical appealed against this decision by the Patent Court in The Hague and the proceeding is pending.

In Germany, AGA Medical won a patent infringement litigation before the appeal court in Dusseldorf. This decision has no relevance outside Germany though.

"Our response to this is threefold," said Tor Peters. "First we decided to appeal the court's decision and initiated a complaint against the appeal court's revision-disallowance. The appeal court's decision is therefore not final, contrary to what was indicated by our competitor. Secondly, we are pursuing invalidation proceedings to invalidate the relevant AGA Medical patent. The case will be heard in Munich in September. Thirdly, we have developed a version of the occluder that does not violate any ruling. This occluder will be launched in Germany before the summer. Manufacturing, development, marketing and sales outside of Germany have not been impacted and will remain unchanged."

Occlusion devices are used to treat structural heart disease, including structural heart defects and abnormalities such as Atrial Septal Defects, (ASD), and Patent Foramen Ovale (PFO, an undesired channel between the heart's two atria, present in up to 25% of the population), in minimally invasive, non-surgical procedures. The market for PFO occluders is expected to expand significantly as the link between PFO and stroke, that is the third most common cause of death, as well as severe migraine becomes increasingly well documented.

    Tor Peters

    Katrin Biedermann
    Tel.: +49-3641-67-51-20

SOURCE Occlutech GmbH
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. AGA Medical Corporation Responds to Occlutech Statement on the Status of the Ongoing Patent Litigation in Europe
2. Occlutech Clarifies Statement Regarding Favourable Opinion Obtained From AIPPI With Regard to Patents Held by AGA Medical
3. Occlutech Obtains Favourable Court Ruling in Patent Litigation in The Hague Against AGA Medical
4. Intellect Neurosciences, Inc. Obtains Validation of European Patent for Alzheimers Vaccine in 19 Countries
5. Botaneco obtains $2.4 million in funding from AVAC
6. Ganeden Biotech Obtains Self-Affirmed GRAS Status for Probiotic Ingredient, GanedenBC30 (Bacillus coagulans GBI-30, 6086)
7. Neptune Technologies & Bioressources Inc. obtains Complementary Medicine approval in Australia for NKO(R)
8. NEXCORE Technology Obtains Licenses for Revolutionary Fluid Management System
9. China Kangtai Cactus Biotech, Inc. Obtains $500,000 Equity Financing
10. PerOs obtains USDA Establishment and Product Licenses for its oral vaccine formulations
11. Biofisica Obtains $2.3 Million in Financing From Investors
Post Your Comments:
(Date:11/24/2015)... , Nov. 24, 2015  Clintrax Global, Inc., a worldwide ... Carolina , today announced that the company has set a ... a 391% quarter on quarter growth posted for Q3 of 2014 ... and Mexico , with the establishment of ... December 2015. --> United Kingdom and ...
(Date:11/24/2015)... ... ... The Academy of Model Aeronautics (AMA), led by its Executive Council, has ... Prix, to represent the First–Person View (FPV) racing community. , FPV racing has exploded ... of racing and several new model aviation pilots have joined the community because of ...
(Date:11/24/2015)... Ltd. (OTCQB: TIKRF) today announced that its Annual General Meeting of Shareholders ... Israel time, at the law offices of Goldfarb Seligman ... Floor, Tel Aviv, Israel . ... to the Board of Directors; , election of Liat ... an amendment to certain terms of options granted to our Chief Executive ...
(Date:11/24/2015)... ... 2015 , ... In harsh industrial processes, the safety of ... can represent a weak spot where leaking process media is a possible hazard. ... , which are designed to tolerate extreme process conditions. They combine rugged design ...
Breaking Biology Technology:
(Date:11/19/2015)... 2015  Based on its in-depth analysis of the ... with the 2015 Global Frost & Sullivan Award for ... presents this award to the company that has developed ... of the market it serves. The award recognizes the ... on customer base demands, the overall impact it has ...
(Date:11/18/2015)... 18, 2015  As new scientific discoveries deepen our ... other healthcare providers face challenges in better using that ... In addition, as more children continue to survive pediatric ... and old age. John M. Maris, M.D ... of Philadelphia (CHOP) . --> John ...
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
Breaking Biology News(10 mins):